{"id":"W4214685750","doi":"10.1136/jitc-2021-003776","title":"Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; American Society of Clinical Oncology; Novartis","keywords":"Medicine; Adverse effect; Dosing; Internal medicine; Oncology; Cancer; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000456055,0.0002491513,0.0006628272,0.0002270644,0.0004427375,0.00001478534,0.0003304332,0.00004870632,0.0003684645],"category_scores_gemma":[0.00001600161,0.0001625462,0.000290775,0.0006054202,0.0001437496,0.0001556206,0.00006022253,0.0003693914,8.436162e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000406819,"about_ca_system_score_gemma":0.0004337337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001903544,"about_ca_topic_score_gemma":0.0001268162,"domain_scores_codex":[0.9975748,0.0001156353,0.0008761121,0.0002386697,0.0008544578,0.000340294],"domain_scores_gemma":[0.9983341,0.00004606361,0.0008452661,0.0004224641,0.0003062267,0.00004589012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2335372,0.03178137,0.2862551,0.0002692523,0.002903864,0.00001751521,0.0166974,0.001333903,0.1922294,0.00001553534,0.002115649,0.2328438],"study_design_scores_gemma":[0.2995303,0.08939952,0.4927825,0.0009764119,0.0003574913,0.00005089568,0.007719755,0.00004265583,0.05021892,0.00005319942,0.05823958,0.0006287693],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896597,0.00664553,0.000008952424,0.0004335452,0.001075435,0.002009497,0.0001298225,0.00001006132,0.00002748114],"genre_scores_gemma":[0.9981884,0.0005757145,0.00008424517,0.0003382035,0.00007594601,0.0002417705,0.000007458222,0.00005662845,0.0004316474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2322151,"threshold_uncertainty_score":0.6628442,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01189213994870178,"score_gpt":0.3023932276310027,"score_spread":0.290501087682301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}